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quantitative variables, but the highest accuracy was found with the 
SUVMAX/SUVLIVER ratio. At a cut-off of 1.5 for the SUVMAX/SU-
VLIVER ratio, the sensitivity and speciﬁcity to detect malignant LN 
invasion was 82% and 93% respectively. 
Conclusion: Integrated FDG-PET/CT has an accuracy which is too 
low to avoid invasive intrathoracic LN staging in patients with NSCLC. 
Moreover, the visual interpretation of the fusion images of the inte-
grated FDG-PET/CT can be conﬁdently replaced by the quantitative 
variable SUVMAX/SUVLIVER, without loss of accuracy for intratho-
racic LN staging. 
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Background and Objectives: Transoesophageal endoscopic ul-
trasound with real time guided ﬁne-needle aspiration (EUS-FNA) 
qualiﬁes as the staging procedure of choice to demonstrate immediate 
irresectability in patients with lung cancer presenting with enlarged 
mediastinal lymph nodes (MLN). This study compared the diagnos-
tic performance of EUS-FNA in lung cancer patients presenting with 
either enlarged or small MLN. 
Design and Patients: A prospective series in unselected lung cancer 
patients referred for EUS-FNA because of suspicion for MLN invasion 
based on the available imaging. Patients were categorized according to 
the transversal diameter of their MLN on CT-scan: group A (all MLN 
<10mm) and group B (at least 1 MLN ≥10mm). A small MLN was 
considered suspicious when either FDG-avid or when lying closely to 
the primary tumor. All patients underwent surgical-pathologic veriﬁca-
tion when EUS-FNA did not demonstrate malignant MLN invasion. 
Diagnostic performance was compared between both groups at the 
patient level (c2-test).
Results: We studied 150 consecutive lung cancer patients (121 men, 
median 65 years), with presumed malignant MLN invasion. In 108 
(72%), there was at least one enlarged MLN, while in 42 (28%), only 
small MLN were found. The sensitivity (with 95% conﬁdence interval) 
to detect malignancy was 98 (92-99)% and 92 (73-99)% for enlarged 
and small MLN, respectively (p=N.S.). The negative predictive value 
of EUS-FNA was 82 (48-97)% and 90 (66-98)% for enlarged and small 
MLN (p=N.S.). EUS-FNA prevented a surgical intervention in 90% 
and 55% of the patients with enlarged or small MLN, respectively. 
Conclusion: Lung cancer patients with suspicious MLN after imaging 
should ﬁrst be staged by EUS-FNA, regardless the size of the MLN. 
However, the moderate negative predictive value of EUS-FNA makes 
surgical-pathologic veriﬁcation still compulsory. 
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Background: Bronchioloalveolar carcinoma (BAC) histologically 
shows a unique replacing growth pattern of tumor cells along the alveo-
lar wall. In 1999, the World Health Organization (WHO) classiﬁcation 
deﬁned BAC as a form of adenocarcinoma with a pure bronchioloal-
veolar growth pattern and no evidence of stromal, vascular, or pleural 
invasion. To date, ground-glass opacity (GGO) on high-resolution com-
puted tomography (HRCT) was well known as one of the characteristic 
ﬁndings of BAC. On the other hand, although BAC is histologically 
subclassiﬁed into mucinous type and non-mucinous type, the differenc-
es in HRCT ﬁndings between two subtypes of BAC have never been 
studied. In this study, we evaluated the differences in HRCT ﬁndings 
between mucinous and non-mucinous BAC.
Methods: Forty-nine patients with BAC less than 3 cm resected be-
tween September 2002 and December 2006 at Shizuoka Cancer Center 
were included. Among 49 BACs, 33 (67%) were subclassiﬁed to non-
mucinous BAC and 16 (33%) were subclassiﬁed to mucinous BAC. 
HRCT ﬁndings in each subtype of BAC were evaluated. 
Results: Table 1 shows HRCT ﬁndings according to subtype of BAC. 
The HRCT ﬁndings included ill-deﬁned margin, consolidation,and 
pseudocavitation were seen more frequently in mucinous BAC com-
pared with non-mucinous BAC (P<0.01). Non-mucinous BAC mainly 
consisted of GGO on HRCT. In contrast, mucinous BAC mainly 
consisted of consolidation on HRCT and the ratio of GGO was less 
than 25% in all cases. Typical HRCT appearance of mucinous BAC is 
shown in Figure 1.
Conclusions: The HRCT ﬁnding of mucinous BAC was clearly dis-
tinguished from non-mucinous BAC. Our present study demonstrated 
that non-mucinous BAC showed heterogeneous HRCT appearance, but 
mucinous BAC showed homogeneous appearance that was ill-deﬁned 
subpleural consolidation with pseudocavitation or air bronchogram sur-
rounded by slight GGO. When these ﬁndings are shown on HRCT, mu-
cinous BAC should be considered as one of the differential diagnoses.
